广济药业(000952) - 2024 Q3 - 季度财报

Financial Performance - The company's operating revenue for Q3 2024 was ¥165,737,525.72, a decrease of 7.19% compared to the same period last year[2]. - The net profit attributable to shareholders was -¥51,930,265.16, representing a decline of 26.13% year-on-year[2]. - The net profit after deducting non-recurring gains and losses was -¥55,984,922.64, down 30.86% from the previous year[2]. - The company reported a net loss of -¥172,457,181.76 for the first nine months of 2024, a significant increase in losses compared to -¥71,794,280.01 in the same period last year[5]. - Net profit for Q3 2024 was a loss of ¥172,457,181.76, compared to a loss of ¥71,794,280.01 in the previous year, indicating a significant decline in profitability[14]. - The total comprehensive income attributable to the parent company was -158,577,188.07 CNY, compared to -66,969,977.88 CNY in the previous period, indicating a significant decline[15]. - Basic and diluted earnings per share were both -0.4498 CNY, down from -0.1892 CNY in the previous period[15]. Assets and Liabilities - Total assets at the end of Q3 2024 amounted to ¥3,109,029,700.47, an increase of 2.62% from the end of the previous year[2]. - Total current liabilities rose to ¥1,172,810,714.08, an increase of 35.41% from ¥865,866,283.65 year-on-year[12]. - The total liabilities increased to ¥1,892,370,597.12, up from ¥1,637,067,663.82, representing a growth of 15.59%[12]. - The company's equity attributable to shareholders decreased by 12.02% to ¥1,199,537,304.87 compared to the end of the previous year[2]. - The equity attributable to shareholders of the parent company decreased to ¥1,199,537,304.87 from ¥1,363,446,043.29, a decline of 12.03%[12]. Cash Flow - The cash flow from operating activities showed a net outflow of -¥48,147,116.27, but improved by 62.67% compared to the same period last year[5]. - Cash inflow from operating activities totaled 758,598,922.30 CNY, an increase from 538,317,622.57 CNY year-over-year[16]. - Cash outflow from operating activities was 806,746,038.57 CNY, compared to 667,283,390.72 CNY in the previous period, resulting in a net cash flow from operating activities of -48,147,116.27 CNY, an improvement from -128,965,768.15 CNY[17]. - The net cash flow from financing activities decreased by 80.45% to ¥155,443,765.73, primarily due to reduced cash inflows from bank loans and other financing activities[6]. - Cash flow from financing activities generated a net inflow of 155,443,765.73 CNY, down from 795,107,867.42 CNY in the previous period[17]. - The company reported cash and cash equivalents at the end of the period of 414,208,602.87 CNY, a decrease from 543,423,723.82 CNY at the end of the previous period[17]. Shareholder Information - The total number of common shareholders at the end of the reporting period is 30,459, with the top 10 shareholders holding a significant portion of the shares[7]. - The largest shareholder, Changjiang Industrial Investment, holds 25.04% of the shares, amounting to 87,592,065 shares[7]. - There were no changes in the top 10 shareholders due to the transfer of shares for margin trading purposes[8]. Operational Metrics - The company reported a significant increase in inventory, which rose by 22.10% to ¥365,063,824.57, primarily due to increased stock of the leading product VB2[5]. - The company experienced a 44.13% increase in management expenses, totaling ¥150,503,843.52, mainly due to increased losses from work stoppages[5]. - Total operating costs increased to ¥628,443,566.80, up 6.03% from ¥591,546,752.64 year-on-year[13]. - Research and development expenses were ¥44,704,949.95, a decrease of 8.67% from ¥48,939,908.18 in the previous year[14]. Meetings and Governance - The company held a temporary shareholders' meeting on September 27, 2024, to approve the election of the new board of directors and supervisory board[9]. - The company announced the election of candidates for the 11th board of directors and supervisory board during the meetings held on September 11 and September 27, 2024[8][9]. - The company has not undergone an audit for the third quarter report[18].